Login to Your Account



Cylene's Series C Raises $44M For CX-3543 Phase II Trials

By Jennifer Boggs


Wednesday, January 24, 2007
With its lead cancer drug, CX-3543, finishing up Phase I development, privately held Cylene Pharmaceuticals Inc. closed a $44 million Series C round to fund upcoming Phase II trials of the small molecule in multiple indications, starting with chronic lymphocytic leukemia. (BioWorld Today)

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription